Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2012, Article ID 654861, 14 pages
http://dx.doi.org/10.1155/2012/654861
Clinical Study

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer

1Section of Oncology, Department of Radiology, Oncology and Radiation Science, Uppsala University Hospital, 751 85 Uppsala, Sweden
2Regional Cancer Centre, Uppsala Orebro, 751 85 Uppsala, Sweden
3Section of Medical Physics, Department of Radiology, Oncology and Radiation Science, Uppsala University Hospital, 751 85 Uppsala, Sweden

Received 17 February 2012; Accepted 17 April 2012

Academic Editor: Rami Ben-Yosef

Copyright © 2012 Silvia Johansson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Proton boost of 20 Gy in daily 5 Gy fractions followed by external beam radiotherapy (EBRT) of 50 Gy in daily 2 Gy fractions were given to 278 patients with prostate cancer with T1b to T4N0M0 disease. Fifty-three percent of the patients received neoadjuvant androgen deprivation therapy (N-ADT). The medium followup was 57 months. The 5-year PSA progression-free survival was 100%, 95%, and 74% for low-, intermediate-, and high-risk patients, respectively. The toxicity evaluation was supported by a patient-reported questionnaire before every consultant visit. Cumulative probability and actuarial prevalence of genitourinary (GU) and gastrointestinal (GI) toxicities are presented according to the RTOG classification. N-ADT did not influence curability. Mild pretreatment GU-symptoms were found to be a strong predictive factor for GU-toxicity attributable to treatment. The actuarial prevalence declined over 3 to 5 years for both GU and GI toxicities, indicating slow resolution of epithelial damage to the genitourinary and gastrointestinal tract. Bladder toxicities rather than gastrointestinal toxicities seem to be dose limiting. More than 5-year followup is necessary to reveal any sign of true progressive late side effects of the given treatment. Hypofractionated proton-boost combined with EBRT is associated with excellent curability of localized PC and acceptable frequencies of treatment toxicity.